LJPC Key Stats
- LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Regulation FD Disclosure, Financi... May 16
- LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Results of Operations and Financi... May 15
- La Jolla Pharmaceutical Company Presents Corporate Update at the MoneyShow Marketwired May 14
- La Jolla Pharmaceutical Company Announces First-Quarter 2013 Financial Results a... May 13
- LA JOLLA PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly Report May 13
- La Jolla Pharmaceutical Company Announces Completion of Phase 1 Portion of GCS-1... May 6
- LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events Apr 28
- La Jolla Pharmaceutical Company Receives Orphan Designation From FDA for LJPC-64... Apr 18
- Abbott: Galectin-3 Assay Sees Approval And Builds Takeover Case For La Jolla Pha... Apr 15
- LA JOLLA PHARMACEUTICAL CO Financials Apr 6
LJPC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). La Jolla Pharmaceutical is up 59.68% over the last year vs S&P 500 Total Return up 30.71%, ARCA biopharma up 1.56%, and Bioline Rx down 27.24%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for LJPC
Pro Report PDF for LJPC
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download LJPC Pro Report PDF
Pro Strategies Featuring LJPC
Did La Jolla Pharmaceutical make it into our Pro Portfolio Strategies?